Biodesix, Inc., a company developing and commercializing molecular diagnostics for personalized medicine, announced that the United States Patent and Trademark Office has awarded to the Company patent number 7,736,905. The patent provides coverage for the Company’s first product, VeriStrat, which is used by physicians to help guide therapy [...]
ARIAD Pharmaceuticals, Inc. announced that the independent Data Monitoring Committee (DMC) of the Phase 3 SUCCEED trial has completed the second interim efficacy analysis as specified in the study protocol and has recommended that the randomized, placebo-controlled trial of oral ridaforolimus in patients with metastatic sarcomas continue to [...]
GTx, Inc. announced top line results of the Phase III clinical trial evaluating toremifene 20 mg, a selective estrogen receptor modulator, for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia, or PIN, a premalignant lesion of the prostate. Source: General Cancer News Articles Provided by [...]
Synta Pharmaceuticals Corp. announced that clinical activity seen in the first stage of its trial for STA-9090 in Stage IIIB and Stage IV patients with non-small cell lung cancer (NSCLC), support advancing to the second stage of the trial. This result was achieved in the first pre-defined patient cohort [...]
Celldex Therapeutics, Inc. announced that the first patient has been screened in a randomized Phase 2 study of the Company’s novel, first-in- class antibody-based vaccine candidate from its Precision Targeted Immunotherapy (PTI) platform. Source: General Cancer News Articles Provided by Cancer Compass
OSI Pharmaceuticals, Inc. announced that it has completed enrollment in the RADIANT study, a Phase III clinical trial testing Tarceva (erlotinib) as an adjuvant therapy in patients with Stage IB-IIIA non- small cell lung cancer (NSCLC) who have undergone surgery and have EGFR-positive tumors. Source: General Cancer News Articles Provided by Cancer [...]
NIH announced today the awarding of 10 new Centers for Population Health and Health Disparities, designed to better understand and address inequities associated with the two leading causes of death in the United States – cancer and heart disease. The program is supported by NCI, NHLBI and the Office of Behavioral and Social Sciences Research. [...]
TrovaGene, Inc., a developer of transrenal molecular diagnostics, announced that LabCorp, one of the world’s leading reference laboratories, and InVivoScribe Technologies, a world leader in molecular hematopathology testing, have notified the Company that they have begun laboratory testing services for the detection of NPM1 mutations for the diagnosis [...]
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) announced positive GVAX AML Vaccine results and BioSante’s receipt of Orphan Drug designation from the FDA’s Office of Orphan Products Development for GVAX AML Vaccine in the treatment of acute myeloid leukemia (AML). This Orphan Drug designation is the second GVAX cancer vaccine [...]
Human Genome Sciences, Inc. announced the results of its randomized Phase 2 trial of mapatumumab (HGS-ETR1) in combination with the chemotherapy agents paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC). Source: General Cancer News Articles Provided by Cancer Compass